{"id":356,"date":"2026-04-12T06:15:49","date_gmt":"2026-04-12T06:15:49","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=356"},"modified":"2026-08-30T03:53:23","modified_gmt":"2026-08-30T03:53:23","slug":"lucipona-ponatinib-45-mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/ru\/product\/lucipona-ponatinib-45-mgx30-tablets\/","title":{"rendered":"LuciPona 45mg"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciPona safely and effectively. See full prescribing information for LuciPona.<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciPona is a kinase inhibitor indicated for the treatment of adult patients with: <\/span><\/p>\n

\u00b7 Chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors. <\/span><\/p>\n

\u00b7 Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated. <\/span><\/p>\n

\u00b7 T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL. <\/span><\/p>\n

Limitations of Use: LuciPona is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

\u2022 Recommended Dosage in CP-CML: Starting dose is 45 mg orally once daily with a reduction to 15 mg once daily upon achievement of \u22641% BCR-ABL1IS. <\/span><\/p>\n

\u2022 Recommended Dosage in AP-CML, BP-CML, and Ph+ ALL: Starting dose is 45 mg orally once daily. <\/span><\/p>\n

\u2022 Hepatic Impairment: Reduce the starting dose to 30 mg orally once daily. <\/span><\/p>\n

\u2022 LuciPona may be taken with or without food. <\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 45 mg\u00d730 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

None.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

 <\/span><\/p>\n

\u2022 Hypertension: Monitor blood pressure and manage hypertension as clinically indicated. Interrupt, dose reduce or stop LuciPona if hypertension is not medically controlled.  <\/span><\/p>\n

\u2022 Pancreatitis: Monitor serum lipase. Interrupt, then resume at the same or reduced dose or discontinue LuciPona based on severity. Evaluate for pancreatitis when lipase elevation is accompanied by abdominal symptoms.<\/span><\/p>\n

\u2022 Neuropathy: Monitor for symptoms of peripheral and cranial neuropathy. Interrupt, then resume at the same or reduced dose or discontinue LuciPona based on recurrence\/severity. <\/span><\/p>\n

\u2022 Ocular Toxicity: Conduct comprehensive eye exams at baseline and periodically during treatment. <\/span><\/p>\n

\u2022 Hemorrhage: Monitor for hemorrhage and manage patients as clinically indicated. Interrupt, then resume at the same or reduced dose or discontinue LuciPona based on recurrence\/severity. <\/span><\/p>\n

\u2022 Fluid Retention: Monitor for fluid retention and manage patients as clinically indicated. Interrupt, then resume at the same or reduced dose or discontinue LuciPona based on recurrence\/severity. <\/span><\/p>\n

\u2022 Cardiac Arrhythmias: Monitor for signs or symptoms of arrhythmias and manage patients as clinically indicated. Interrupt, then resume at the same or reduced dose or discontinue LuciPona based on recurrence\/severity. <\/span><\/p>\n

\u2022 Myelosuppression: Obtain complete blood counts every 2 weeks for the first 3 months and then monthly or as clinically indicated. If ANC less than 1 x 109<\/span><\/sup>\/L or platelets less than 50 x 109<\/span><\/sup>\/L, interrupt LuciPona until ANC at least 1.5 x 109<\/span><\/sup>\/L and platelets at least 75 x 109<\/span><\/sup>\/L, then resume at same or reduced dose. <\/span><\/p>\n

\u2022 Tumor Lysis Syndrome: Ensure adequate hydration and correct elevated uric acid levels prior to initiating LuciPona. <\/span><\/p>\n

\u2022 Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Interrupt LuciPona until resolution. The safety of resumption of LuciPona in patients upon resolution of RPLS is unknown.<\/span><\/p>\n

\u2022 Impaired Wound Healing and Gastrointestinal Perforation: Withhold LuciPona for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LuciPona after resolution of wound healing complications has not been established.<\/span><\/p>\n

\u2022 Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.<\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

The most common (>20%) adverse reactions are rash and related conditions, arthralgia, abdominal pain, headache, constipation, dry skin, hypertension, fatigue, fluid retention and edema, pyrexia, nausea, pancreatitis\/lipase elevation, hemorrhage, anemia, hepatic dysfunction and AOEs. The most common Grade 3 or 4 laboratory abnormalities (>20%) are platelet count decreased, neutrophil cell count decreased, and white blood cell decreased. <\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Strong CYP3A Inhibitors: Avoid coadministration or reduce LuciPona dose if coadministration cannot be avoided. <\/span><\/p>\n

\u2022  Strong CYP3A Inducers: Avoid coadministration.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

Lactation: Advise not to breastfeed. <\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u2103 to 25\u2103 (68\u2109 to 77\u2109), excursions permitted between 15\u2103 and 30\u2103 (59\u2109 and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

It is suitable for the treatment of adult patients with chronic phase (CP) chronic myelogenous leukemia (CML).<\/p>","protected":false},"featured_media":1805,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[21],"product_tag":[],"class_list":["post-356","product","type-product","status-publish","has-post-thumbnail","product_cat-blood-disease","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product\/356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/comments?post=356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/media\/1805"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/media?parent=356"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product_brand?post=356"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product_cat?post=356"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product_tag?post=356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}